中山医院正在构建智能化的介入"元导管室"。目前，包括AI智能体、介入手术机器人在内的高科技设备 和软件都已经开始逐步融入应用。 6月1日，第十九届东方心脏病学会议OCC 2025（下称"东方会"）闭幕。在今年的东方会上，AI医疗成 为最大的亮点——介入手术机器人、智能导管室、AI智能体等极具科幻性的场景正在逐渐走进医院手 术室。 在大会上，复旦大学附属中山医院心内科李晨光教授和陆浩教授等远程展示了AI在复杂冠脉介入手术 中的辅助作用，并通过语音问答与介入医生智能体实时交互。智能体精准调阅出患者信息、既往病史、 影像报告等多模态信息，并实现智能化读取影像结果，辅助医生进行术前精准规划。 哈尔滨医科大学附属第二医院于波教授在项目科学设计汇报中表示："介入手术机器人是一个不可阻挡 的趋势，早期肯定不完善，但一定要敢于跨出第一步，支持介入手术机器人的发展。" 他还特别强调："多中心研究不是简单验证机器人的实用性与安全性，而是要通过多维度数据挖掘，揭 示机器人操作在手术操作控制、力反馈能力等方面的独特规律，为推动具有中国特色的介入机器人应用 发展提供依据。" 中山医院正在构建智能化的介入"元导管室"。目前，包括AI智能 ...

以下文章来源于21世纪商业评论 ，作者何己派 21世纪商业评论 . 《21世纪商业评论》敏感于一切商业新知、商业产品、商业模式和商业英雄，敏感于新公司的新玩意、老公司 的新改造、旧话题的新表达、老商业的新颠覆，为您提供最新鲜实用的商业养分。 研发药物，大笔融资。 来源：21世纪商业评论 记者：何己派 编辑：鄢子为 三位麻省理工的博士，延迟现金到账的时间。 5月26日，晶泰科技发布公告，联合创始人温书豪、马健及赖力鹏博士，自愿延长所持股票禁售期一 年。 原本，三人在6月中旬就可套现，尝到财务自由的甜头；现在其承诺，到2026年6月12日止，不会出 售手头股票。 | THE OF THE FOR THE | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 职务 | 任职日期 | 性别 | 出生年份 | 年龄 | 最新薪酬(万元) | 最新持股数(万股) | | > 温书豪 | 董事长,执行董事 | 2023-11-27 | | 1982 | 43 | 4,910.40 | 80,993.85 | | ■> 蒋一律 | 执 ...

Core Viewpoint - The company is focusing on expanding its product offerings in AI healthcare, brain-machine interfaces, rehabilitation robots, and other areas to meet clinical and elder care market demands while maintaining its technological leadership in the rehabilitation industry [2][3]. Product Development and Market Strategy - The company plans to launch more products in AI healthcare, brain-machine interfaces, and rehabilitation robots to enhance its overall R&D capabilities and meet market needs [2]. - The brain-machine interface products are applicable in various fields such as neural rehabilitation, education, VR, smart living, military engineering, and entertainment [6]. - The company is developing a series of rehabilitation robots, with a focus on medical-grade versions for hospitals and rehabilitation centers, while also planning to introduce home-use versions in the long term [2][4]. Financial Performance and Projections - In 2024, the company faced challenges due to delays in bidding activities in the medical field, leading to a slight decline in revenue. However, it anticipates a recovery in net profit by 2025 as expenses stabilize [3]. - The company's revenue for Q1 2025 was 186.05 million yuan, a year-on-year increase of 10.02%, while net profit decreased by 41.26% to 22.95 million yuan [15]. - The company aims to improve its financial performance by enhancing its product offerings and expanding into home rehabilitation markets [13][14]. Research and Development Focus - The company has established the Sun-BCI Lab to focus on brain-machine interface research, with plans to launch over 20 products by 2025, including EEG machines and psychological products [5]. - The company is committed to developing intelligent rehabilitation devices across various domains, including pain rehabilitation, neurological rehabilitation, and geriatric care [7][10]. Market Position and Sales Strategy - The company has a strong market presence in rehabilitation medical devices, with a comprehensive product range covering various rehabilitation needs [11]. - The company is exploring partnerships with leading insurance and elder care companies to enhance its market reach and product commercialization [9][10]. - The company is also focusing on expanding its sales channels beyond hospitals to include outpatient and home care settings [8][13].

Group 1 - The innovative drug sector is experiencing significant growth, with the biopharmaceutical ETF (159508) rising by 1.90% and attracting over 10 million yuan in net inflows yesterday [1] - Notable stocks in the sector include Junshi Biosciences-U and Dizal Pharmaceuticals-U, both rising over 6%, along with other companies like Kelun Pharmaceutical, Hangzhou Tigermed Consulting, and WuXi AppTec also seeing gains [1] - Year-to-date, ETFs focused on Hong Kong innovative drugs and biotechnology have shown strong performance, with gains exceeding 32%, while 90% of pharmaceutical-themed funds have reported positive growth this year [1] Group 2 - The innovative drug sector is one of the few growth areas within the overall pharmaceutical industry, with a favorable environment for commercialization and increasing self-sustainability among domestic innovative drugs [2] - Future trends in medical insurance spending are expected to support the payment growth for innovative drugs, with collaboration between commercial insurance and medical insurance entering a rapid development phase [2] - The outlook for the pharmaceutical industry is becoming increasingly positive, indicating a potential for significant advancements in the sector [2]

Group 1 - The A-share market saw a positive trend with the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index rising by 1.95% as of the report time [1] - The Science and Technology Innovation Medicine Index ETF (588700) increased by 2.18%, with a turnover rate of 8.76% and a transaction volume exceeding 23.75 million [1] - Among the constituent stocks, Yifang Biotechnology-U surged over 12%, Borui Pharmaceutical rose over 8%, and Microchip Biotech increased over 7% [1] Group 2 - According to Industrial Securities, the innovative drug sector's prosperity is expected to be sustainable, with "innovation + internationalization" remaining the core direction of the pharmaceutical sector [2] - The report highlights that the innovative drug industry chain's fundamentals are beginning to improve, with overseas orders and performance starting to recover [2] - The demand in the domestic market is anticipated to rebound by 2025, with potential recovery in the consumption medical field, including medical services and OTC traditional Chinese medicine [2]

Group 1 - The pharmaceutical sector is experiencing renewed activity, particularly in CRO, innovative drugs, and medical services, with significant gains in related ETFs [1] - The Biopharmaceutical ETF (159859) rose by 1.7%, with trading volume exceeding 50 million yuan, while the Innovative Drug ETF Tianhong (517380) increased by 1.66%, with several constituent stocks rising over 5% [1] - The Biopharmaceutical ETF closely tracks the National Biopharmaceutical Index (399441.SZ) and is the largest product in its category, also offering a connecting fund [1] Group 2 - The ASCO annual meeting, a major platform for biopharmaceutical companies to present clinical research results, will take place from May 30 to June 3, 2025, in Chicago and online [2] - The innovative drug sector is highlighted as a key focus for the year, with attention on areas such as anti-tumor, autoimmune, GLP-1, stem cells, and gene therapy, alongside domestic pharmaceutical consumption and medical aesthetics [2] - The innovative drug sector is expected to maintain its growth, supported by policy, global competitiveness, and improving fundamentals, with a potential recovery in demand anticipated by 2025 [2]

Group 1 - The Hong Kong stock market showed mixed performance, with the Hang Seng Index down 0.02% and the Hang Seng Tech Index up 0.19% [1] - The Hong Kong Innovative Drug ETF (159567) increased by 0.39%, with a turnover rate of 4.08% and a trading volume exceeding 660 million yuan, indicating active trading [1] - Notable stocks within the ETF included WuXi AppTec, which rose over 5%, WuXi Biologics, which increased over 4%, and Kelun Pharmaceutical, which gained over 2% [1] Group 2 - The innovative drug and AI medical sectors performed actively in Q1, with related fund products showing impressive returns, as the top-performing ETFs have all exceeded a 32% increase year-to-date [1] - The majority of pharmaceutical-themed funds have also shown positive growth, with 90% reporting positive performance for the year [1] - Industry analysts from Industrial Securities expect a steady recovery in the pharmaceutical sector due to favorable policies, particularly in the hospital market, which was previously impacted by anti-corruption and centralized procurement [1] Group 3 - Minsheng Securities highlighted continuous catalysts in the innovative drug sector, focusing on areas such as anti-tumor, autoimmune, GLP-1, stem cell, and gene therapy, while also emphasizing the importance of domestic substitution and medical consumption, particularly in the beauty sector [2]

"拿了快五年的医药主题基金终于开始赚钱了。"近日医药行情持续回暖，让很多投资者眼前一亮。随着 相关板块特别是创新药这一细分领域逐渐受到市场关注，多家公募基金公司纷纷开始宣推医药主题基 金，多位医药基金经理频频亮相发声。 在公募机构人士看来，医药行情回暖并不是短期市场情绪推动那么简单。经历近五年的调整后，原先制 约医药板块表现的多个负面因素正逐渐消退。医药板块，特别是创新药领域涌现出许多新变化。多位基 金经理表示，看好后续医药板块尤其是创新药细分领域的投资机会。 ● 本报记者 张韵 医药主题基金水涨船高 近期，医药板块行情持续回暖，多只医药主题基金也收获了不同程度的涨幅。 以被动产品为例，主投医药尤其是港股医药品种的ETF近期表现突出。5月20日，多只港股创新药ETF 跳空高开，截至当日收盘，全市场涨幅前十的ETF中有8只为港股创新药产品，涨幅全部超过4%。5月 23日，创新药ETF再度领涨，一只创新药产品位居全市场ETF涨幅榜首位。5月27日，医药主题ETF再度 领涨，港股创新药ETF占据全市场ETF涨幅前六位置。 Wind数据显示，截至5月28日，今年以来全市场涨幅前十的ETF均为主投港股医药的产品，涨幅均 ...

Core Insights - Leo International Group has successfully completed the transfer of control of a company listed on the Frankfurt Stock Exchange, now renamed Leo International Precision Health Aktiengesellschaft (LIPH AG), marking the first Taiwanese company to list on this exchange [1][10] - The company aims to leverage its new listing to expand into the European market, focusing on a "Precision Health Trinity" strategy that includes AI-driven pharmaceuticals, diagnostics, and community healthcare services [5][10] Group 1: Company Strategy and Positioning - The company plans to establish a Single Family Office (SFO) in Singapore, reflecting its commitment to long-term family legacy and investment in the healthcare sector [8][13] - The "Precision Health Trinity" strategy will focus on AI-driven solutions for both common and rare diseases, aiming for rapid expansion through non-organic growth strategies [5][10] - The company holds 80% of the shares in LIPH AG, with original shareholders converting their shares to enjoy liquidity in the international capital market [10][11] Group 2: Market Trends and Opportunities - Singapore is positioned as a hub for family offices, with over 2,000 SFOs expected by 2024, driven by a stable political environment and tax incentives [3] - The German biotechnology and medical technology sectors saw investments of €1.6 billion in the first nine months of 2024, a 70% increase year-on-year, indicating a growing interest in the health industry [3] - The digital pathology market is projected to grow from $8.1 billion in 2024 to $19.5 billion by 2031, highlighting the accelerating shift towards technology-driven precision health [3] Group 3: Future Plans and Global Expansion - The company is exploring dual listing in the U.S. and potential listing in Singapore to enhance its market presence [7][11] - Future strategies include attracting international sovereign funds and multinational capital groups to invest in the precision health platform [5][11] - The CEO emphasizes the importance of optimizing corporate governance and financial flexibility to support sustainable global operations [11]

Macro Dynamics - The Chinese Foreign Ministry urged the U.S. to ensure the legitimate rights and interests of international students, including Chinese students, amid reports of a halt in student visa issuance [1] - China announced a trial visa exemption policy for Saudi Arabia, Oman, Kuwait, and Bahrain from June 9, 2025, to June 8, 2026, allowing ordinary passport holders from these countries to enter China without a visa for up to 30 days [2] Market Data - From May 1 to 25, the retail sales of passenger cars in China reached 1.358 million units, a year-on-year increase of 16%, with a cumulative retail of 8.23 million units for the year, up 9% [3] - The retail sales of new energy vehicles during the same period were 726,000 units, marking a 31% year-on-year increase, with a penetration rate of 53.5% [3] - From January to April, the total profit of state-owned enterprises was 1.34914 trillion yuan, a year-on-year decrease of 1.7% [4] Company Dynamics - China’s Ministry of Education reported that the number of candidates for the national college entrance examination in 2025 is expected to reach 13.35 million [5] - The first-instance trial of former chairman of Everbright Trust, Yan Guijun, for bribery and abuse of power began, with allegations of illegal loan approvals totaling over 6.39 billion yuan [7] - Stellantis announced Antonio Filosa as the new CEO, effective June 23, 2024, following his extensive experience within the company [15] - Douyin e-commerce plans to reduce freight insurance costs for merchants by 5% to 15% starting June 6, 2024, potentially saving over 1 billion yuan in operating costs for merchants in the coming year [17]